Drugs / UCMSC-Exo

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06245746 Feb 2025 → Feb 2026 overdue acute myeloid leukemia, anemia, hemorrhagic disease, infectious disease +2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07638813 Jul 2026 → Oct 2027 expected frontotemporal dementia Ruijin Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT06896747 Feb → Jun 2025 overdue adhesions of uterus, female infertility Tang-Du Hospital Recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as UCMSC-Exo “Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning.” NCT06896747
1

NCT06245746

Known as MSC-Exos “Participants randomized to the low-dose group will receive intranasal spray of human umbilical cord mesenchymal stem cell-derived exosomes (MSC-Exos), 1 mL per administration...” NCT07638813
Known as umbilical cord derived mesenchymal stem cells exosomes umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)” NCT06245746
Known as Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638813
Action Restore “promote the repairment and regeneration of key cells such as hematopoietic stem cells, mesenchymal stem cells and endothelial cells” NCT06245746
Modality Other / unclassified “umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)” NCT06245746
Route Intravenous “UCMSC-Exo will be infused intravenously.” NCT06245746